NO20092045L - Macrocyclic quinazoline derivatives as VEGFR3 inhibitors - Google Patents

Macrocyclic quinazoline derivatives as VEGFR3 inhibitors

Info

Publication number
NO20092045L
NO20092045L NO20092045A NO20092045A NO20092045L NO 20092045 L NO20092045 L NO 20092045L NO 20092045 A NO20092045 A NO 20092045A NO 20092045 A NO20092045 A NO 20092045A NO 20092045 L NO20092045 L NO 20092045L
Authority
NO
Norway
Prior art keywords
vegfr3
quinazoline derivatives
inhibitors
macrocyclic quinazoline
macrocyclic
Prior art date
Application number
NO20092045A
Other languages
Norwegian (no)
Inventor
Timothy Pietro Suren Perera
Matthias Luc A Versele
Martin John Page
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NO20092045L publication Critical patent/NO20092045L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Den foreliggende oppfinnelsen relaterer seg til anvendelsen av noen av de makrocykliske quinazolinderivatene beskrevet i PCT-publikasjonWO2004/105765 som inhibitorer av VEGFR3-medierte biologiske aktiviteter, særlig de aktivitetene som er mediert vedVEGFR3-ligander VEGF-C og/eller VEGF-D.The present invention relates to the use of some of the macrocyclic quinazoline derivatives disclosed in PCT Publication WO2004 / 105765 as inhibitors of VEGFR3-mediated biological activities, in particular those activities mediated by VEGFR3 ligands VEGF-C and / or VEGF-D.

NO20092045A 2006-10-27 2009-05-26 Macrocyclic quinazoline derivatives as VEGFR3 inhibitors NO20092045L (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US86319806P 2006-10-27 2006-10-27
EP06123056 2006-10-27
US97621007P 2007-09-28 2007-09-28
PCT/EP2007/061499 WO2008049902A2 (en) 2006-10-27 2007-10-25 Macrocyclic quinazoline derivatives as vegfr3 inhibitors

Publications (1)

Publication Number Publication Date
NO20092045L true NO20092045L (en) 2009-06-26

Family

ID=39324960

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20092045A NO20092045L (en) 2006-10-27 2009-05-26 Macrocyclic quinazoline derivatives as VEGFR3 inhibitors

Country Status (11)

Country Link
EP (1) EP2077845A2 (en)
JP (1) JP2010507626A (en)
KR (1) KR20090089849A (en)
AU (1) AU2007310843A1 (en)
BR (1) BRPI0718061A2 (en)
CA (1) CA2664148A1 (en)
EA (1) EA200970419A1 (en)
IL (1) IL198346A0 (en)
MX (1) MX2009004436A (en)
NO (1) NO20092045L (en)
WO (1) WO2008049902A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA83881C2 (en) 2003-12-18 2008-08-26 Янссен Фармацевтика Н.В. Pyrido- and pyrimidopyrimidine derivatives as anti-proliferative agents
NI200700147A (en) 2004-12-08 2019-05-10 Janssen Pharmaceutica Nv QUINAZOLINE DERIVATIVES KINE INHIBITORS TARGETING MULTIP
MX2009000456A (en) 2006-07-13 2009-01-27 Janssen Pharmaceutica Nv Mtki quinazoline derivatives.
EP2185562B1 (en) 2007-07-27 2015-12-02 Janssen Pharmaceutica, N.V. Pyrrolopyrimidines useful for the treatment of proliferative diseases
JP2013523843A (en) * 2010-04-15 2013-06-17 ベジェニクス ピーティーワイ リミテッド Combination treatment with VEGF-C antagonist
MX349366B (en) * 2011-05-19 2017-07-26 Centro Nac De Investigaciones Oncologicas (Cnio) Macrocyclic compounds as protein kinase inhibitors.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2785B1 (en) * 2003-05-27 2014-03-15 شركة جانسين فارماسوتيكا ان. في Quinazoline derivatives
UA83881C2 (en) * 2003-12-18 2008-08-26 Янссен Фармацевтика Н.В. Pyrido- and pyrimidopyrimidine derivatives as anti-proliferative agents
JO3088B1 (en) * 2004-12-08 2017-03-15 Janssen Pharmaceutica Nv Macrocyclic Quinazoline derivatives and their use as MTKI

Also Published As

Publication number Publication date
AU2007310843A1 (en) 2008-05-02
MX2009004436A (en) 2009-05-22
CA2664148A1 (en) 2008-05-02
IL198346A0 (en) 2010-02-17
JP2010507626A (en) 2010-03-11
BRPI0718061A2 (en) 2013-11-05
WO2008049902A3 (en) 2008-10-02
EP2077845A2 (en) 2009-07-15
EA200970419A1 (en) 2009-10-30
WO2008049902A2 (en) 2008-05-02
KR20090089849A (en) 2009-08-24

Similar Documents

Publication Publication Date Title
EA201170227A1 (en) ИМИДАЗОЛКАРБОКСАМИДЫ
MX354402B (en) Small molecule inhibitors of the pleckstrin homology domain and methods for using same.
WO2009044173A3 (en) Methods of treating cancer using notch pathway inhibitors
MY170509A (en) Activin-actrii antagonists for use in treating anemia
ATE516286T1 (en) 5-(Ä1,3,4ÜOXADIAZOLE-2-YL)-1H-INDAZOLE AND 5-(Ä1,3,4ÜTHIADIAZOL-2-YL)-1H-INDAZOLE DERIVATIVES AS SGK INHIBITORS FOR THE TREATMENT OF DIABETES
MX2009011002A (en) Ischemia/reperfusion protection compositions and methods of using.
NO20091326L (en) Indazole derivatives as modulators of interleukin-1 receptor-associated kinase
CL2012003048A1 (en) Compounds derived from n-phenyl-3- (1h-pyrazol-4-yl) quinoxalin-6-amine, fgfr tyrosine kinase inhibitors; Preparation process; pharmaceutical composition; and its use in the prevention or treatment of cancer.
EA201170521A1 (en) NEW CONNECTIONS
EA201170252A1 (en) AMIDOPHENOXINDAZOLES AS C-MET INHIBITORS
MX2008008152A (en) Bicyclic heteroaryl compounds.
MY163477A (en) Pyrimidinyl-pyridazinone derivatives
EA200701802A1 (en) IMIDAZO (1,2-A) PYRIDINE CONNECTIONS AS VEGF-R2 INHIBITORS
UA101478C2 (en) Compounds useful as inhibitors of raf protein kinase
ATE489371T1 (en) BENZAMIDE GLUCOCINASE ACTIVATORS
WO2008086462A3 (en) AMINO-SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF β-CANTENIN/TCF-4 PATHWAY AND CANCER TREATMENT AGENTS
NO20092045L (en) Macrocyclic quinazoline derivatives as VEGFR3 inhibitors
MX2008001538A (en) 2-aminoaryl pyridines as protein kinases inhibitors.
MX2010009743A (en) Use of pyrimidine derivatives for the treatment of egfr dependent diseases or diseases that have acquired resistance to agents that target egfr family members.
ATE458740T1 (en) 1,4,5,6,7,8-HEXAHYDRO-1,2,5-TRIAZA-AZULENE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS
GEP20115201B (en) Cinnamoyl-piperazine derivatives and their use as par- i antagonists
MX2009006812A (en) Modulators of c3a receptor and methods of use thereof.
EA201000329A1 (en) CYCLIC DEPSIPEPTIDES
NO20093542L (en) Inhibition of tumor metastasis by anti-neuropilin 2 antibodies
MX342947B (en) Treatment of type 2 diabetes.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application